Mealey's (May 5, 2023, 12:01 PM EDT) -- WASHINGTON, D.C. — In a win for an oncology company, the Federal Circuit U.S. Court of Appeals on May 5 vacated and remanded findings by the Patent Trial and Appeal Board that a system and method for detecting rare mutations and copy number variations in cell free DNA (cfDNA) would be obvious to a person of skill in the art....